Research Interests of our laboratory
1. Carcinogenic and anticancer actions of various endogenously-formed estrogen metabolites.
2. Physiological actions exerted by the endogenous estrogen metabolites.
3. Pharmacological actions of naturally-occurring compounds (such as dietary phenolic antioxidants and fatty acids) and their potential use as therapeutic agents in humans.
Selected Recent Publications
Fu X and Zhu BT [2009] Human pancreas-specific protein disulfide isomerase homolog (PDIp) is an intracellular estrogen-binding protein that modulates estrogen levels and actions in target cells. Journal of Steroid Biochemistry and Molecular Biology 115: 20-29.
Zhou R, Fukui M, Choi HJ and Zhu BT [2009] Induction of a reversible, non-cytotoxic S phase delay by resveratrol: Implications for a mechanism of lifespan prolongation and cancer protection. British Journal of Pharmacology (in press).
Fukui M and Zhu BT [2009] Mechanism of 2-methoxyestradiol-induced apoptosis and growth arrest in human breast cancer cells. Molecular Carcinogenesis 48: 66-78.
Zhu BT, Wang P, Nagai M, Wen Y and Bai HW [2008] Inhibition of human catechol-O-methyltransferase (COMT)-mediated O-methylation of catechol estrogens by major polyphenolic components present in coffee. Journal of Steroid Biochemistry and Molecular Biology 113: 65-74.
Fu X, Wang P and Zhu BT [2008] Protein disulfide isomerase is a multifunctional regulator of estrogenic status in target cells. Journal of Steroid Biochemistry and Molecular Biology 112: 127-137.
Contact Information
B. T. Zhu, Ph.D.
Professor
Department of Pharmacology, Toxicology, & Therapeutics
The University of Kansas Medical Center
MS 1018, KLSIC 4061
3901 Rainbow Blvd.
Kansas City, KS 66160
Phone: (913) 588-9842
Fax: (913) 588-7501
E-mail address: btzhu@kumc.edu
Updated 8/10/09
©
The University of Kansas Medical Center